Accelerating Novel Diagnostic Solutions for Alzheimer’s Disease

The ALZpath difference

ALZpath provides diagnostic tools and expertise in Alzheimer’s disease.  We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer’s disease.

Blood-based biomarker (pTau217) for the early diagnosis of Alzheimer’s disease
Innovative diagnostic tools for various contexts of use
Track over time the impact of a treatment or the progression of an individual’s Alzheimer’s disease
Clinical trial and emerging therapies screening and stratification

A timely and accessible diagnosis

Our novel and proprietary diagnostic blood test is the only commercially available test for phosphorylated tau 217 (pTau217). We offer an approach to diagnosis that is:

  • Simple
  • Accessible
  • Timely
  • Cost-effective
  • Less invasive

pTau217 can be measured in blood to gain valuable information about what is occurring in the brain. This powerful diagnostic tool can identify key markers of Alzheimer’s disease in the brain prior to the onset of cognitive symptoms.

Recent ALZpath News

ALZpath Announces Strategic Partnership with Alamar Biosciences

February 29, 2024

ALZpath has partnered with Alamar Biosciences to integrate ALZpath pTau217 antibodies into Alamar’s NULISA™ platform. Through integrating ALZpath’s pTau217 antibody into its NULISAqpcr™ pTau-217 Assay, as well as in their multiplexed NULISAseq™ CNS Disease Panel 120. Together, we are driving breakthroughs in understanding neurodegenerative diseases. This collaboration marks a significant milestone in advancing novel tools for neurodegenerative disease research.

ALZpath pTau217 Measured in Dried Blood Spots as Effective Method for Remote Settings

January 29, 2024

In a recent study published in Alzheimer’s & Dementia, researchers present groundbreaking findings on the precision of pTau217 biomarker measurements in dried blood spots. This important study highlights the potential to extend ALZpath pTau217 diagnostic capabilities to remote settings, offering simplified sampling conditions and storage logistics using dried blood spots.

New Study in JAMA Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test

January 22, 2024

The ALZpath pTau217 assay has been featured in a crucial evaluation of biomarkers of Alzheimer’s disease pathology published today in JAMA Neurology. Dr. Ashton and colleagues demonstrated that our ALZpath pTau217 assay can accurately identify and longitudinally monitor Alzheimer’s disease pathology, including in preclinical stages, comparable to CSF and PET tests. Tools like the ALZpath pTau217 test will be vital to screening and treating patients at scale, optimizing outcomes, and reducing long-term costs.

ALZforum Spotlights the Clinical Launch of ALZpath pTau217

December 1, 2023

We are thrilled that ALZforum highlighted the clinical launch of ALZpath pTau217 in their article last week. This feature included key contributions from our esteemed Chief Scientific Officer, Dr. Andreas Jeromin.  

ALZpath is immensely proud of the contributions made by Dr. Andreas Jeromin and the entire team, and we’re excited to witness the impact of ALZpath pTau217 in the quest to better understand and manage Alzheimer’s disease.